Here’s a glimpse into this hedge fund guru’s Q2 moves that reeled back in three biotech players.
PTCT rises back amid hope for approval in nmDMD; DXCM suffers from new competition in diabetes market.
Canaccord analysts debating the impact of recent events on Zynerba and DexCom.
Investors continue to dump shares of DexCom, Inc. (NASDAQ:DXCM) following the news that competitor Abbott Laboratories (NYSE:ABT) received FDA approval for its FreeStyle …
DexCom, Inc. (NASDAQ:DXCM) shares shot up nearly 5% this afternoon, after Apple CEO Tim Cook revealed that the Apple Watch will be equipped to communicate …
DexCom, Inc. (NASDAQ:DXCM) stock has received a string of buy ratings from analysts following a surprise ruling from the U.
Oppenheimer analyst Steven Lichtman reiterates an Outperform rating on shares of DexCom, Inc.(NASDAQ:DXCM), following the Center for Medicare & Medicaid Services’ (CMS) announcement that Dexcom’s …
DexCom, Inc. (NASDAQ:DXCM) shares rose nearly 30% today, after the U.
Over the last couple of years, the very mention of the word “apple” first draws up a sleek, white, bitten-off reflection of the …
